Twelve days after tumor implantation (5 days after the start of therapy) (Figure 2A), we first noted that the combination Vax/aGITR/aPD-1 therapy had the highest increase of tetramer-specific CD8+ T cell responses in the tumors (Figure 6A). This evidence concerns the gene CD8A and neoplasm.